Compare DexCom, Inc. (DXCM) vs Goodyear Tire & Rubber Co (GT) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Goodyear Tire & Rubber (GT) trades at $6.66, up 0.3% with neutral technical signals. The stock shows mixed fundamentals with attractive valuation ratios (P/E 4.69, P/B 0.64) but negative profitability (ROE -52.56%, net margin -11.64%). Recent Q1 2026 earnings beat estimates despite a loss, while the company transitions to S&P SmallCap 600. Cash flow improved in 2025 with $46M net inflow, though revenue declined to $18.28B.

Outlook remains challenging with declining revenue and negative margins, though deep value metrics and analyst consensus target of $8.75 suggest upside potential. Key risks include persistent operational headwinds, weak tire demand, and high debt levels. The Goodyear Forward program and lunar tire contract provide strategic catalysts amid competitive pressures.